A5100683755- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Bone and Dental Protein Studies
- Esophageal and GI Pathology
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Vascular Malformations and Hemangiomas
- Diabetes and associated disorders
- Viral-associated cancers and disorders
- Nausea and vomiting management
- Diagnosis and treatment of tuberculosis
- Congenital heart defects research
- Tissue Engineering and Regenerative Medicine
- Epigenetics and DNA Methylation
- Tuberculosis Research and Epidemiology
- Chromatography in Natural Products
- Pancreatitis Pathology and Treatment
Chinese Academy of Sciences
2022-2024
Zhejiang Cancer Hospital
2011-2024
Cancer Hospital of Chinese Academy of Medical Sciences
2021-2024
University of Chinese Academy of Sciences
2021-2024
Second Affiliated Hospital of Xi'an Jiaotong University
2023
Hangzhou Cancer Hospital
2016
Beijing Hospital
2009
Quanta Computer (China)
2007
University of Cologne
2002
University of Bonn
2002
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve ESCC were randomized (1:1) to receive toripalimab or placebo in combination paclitaxel plus cisplatin (TP) every weeks up 6 cycles, followed by maintenance. At prespecified final analysis of progression-free survival (PFS), a significant improvement PFS observed arm over (hazard ratio...
PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab TKI-resistant, nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults...
In the randomized phase III KEYNOTE-181 study, pembrolizumab prolonged overall survival (OS) compared with chemotherapy as second-line therapy in patients advanced esophageal cancer and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10. We report a post hoc subgroup analysis of squamous cell carcinoma (ESCC) enrolled Asia, including from China extension study.Three hundred forty Asian advanced/metastatic ESCC were KEYNOTE-181, cohort. Patients randomly assigned : to receive...
8097 Background: Treatment options for ES-SCLC in second-line setting are limited. HTMC0435, an oral PARP inhibitor, significantly reduced the ability of to repair DNA damage and inhibited tumor cell proliferation when combined with temozolomide (TMZ) preclinical studies. We investigated safety activity this regimen relapsed SCLC. Methods: This was a phase Ⅰb/Ⅱ dose-escalation (3+3 design) dose-expansion study. patients who had progressed after first- or therapy were eligible. Pts...
Background. Recent progress in the cardiotypic differentiation of embryonic and somatic stem cells opens novel prospects for treatment cardiovascular disorders. The aim present study was to develop a surgical approach that allows standardized cellular cardiomyoplasty mouse with low-perioperative mortality. Methods. Reproducible transmural lesions were generated by cryoinjury followed intramural injection cardiomyocytes using newly designed holding device vital dye staining. This validated...
Chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are controversial in the treatment of patients with brain metastases from non-small-cell lung cancer (NSCLC).We retrospectively studied effects solely localized or combination chemotherapy and/or EGFR on outcomes 210 NSCLC metastases. The modality, Karnofsky performance status, age, primary tumor histology, number metastases, other factors survival time were analyzed, robustness two prognostic indices, ie,...
// Yun Fan 1,2 , Youhua Jiang 3 Xinming Zhou Qixun Chen Zhiyu Huang 1 Yanjun Xu Lei Gong Haifeng Yu Haiyan Yang Jinshi Liu Tao Qiang Zhao and Weimin Mao Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China 2 Key Laboratory Diagnosis Treatment Technology on Thoracic Oncology Research Institute, Surgery, Correspondence to: Mao, email: Keywords : esophageal squamous cell carcinoma; nab-paclitaxel; cisplatin; neoadjuvant chemotherapy; esophagectomy Received February 13,...
In ORIENT-15 study, sintilimab plus chemotherapy demonstrated significant improvement on overall survival (OS) versus placebo in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). Here, we report effect health-related quality life (HRQoL) patients with ESCC.
Rationale: Platinum-based chemotherapy is one of treatment mainstay for patients with advanced lung squamous cell carcinoma (LUSC) but it still a "one-size fits all" approach. Here, we aimed to investigate the predictive and monitoring role circulating cell-free DNA (cfDNA) profiling outcome first-line in LUSC. Methods: Peripheral blood samples 155 from phase IV trial 42 cases an external real-world cohort were prospectively collected. We generated copy number variations-based classifier via...
Plain Language SummaryWhat is this summary about?This study about the effects of a medicine called lorlatinib (Lorbrena) in people from China with advanced ALK-positive non-small cell lung cancer (NSCLC) who had been treated before other medicines. This contains updated results on after 3 years observation. People were put into 2 groups based medicines they taken study. Group 1 crizotinib (Xalkori). types similar medicine, and some them also crizotinib. In study, everyone took lorlatinib....
Plain Language SummaryWhat is this summary about?This describes early (not final) results of a clinical study called CHOICE-01. The looked at the effect medicine toripalimab when added to standard chemotherapy (chemicals used stop growth or kill cancer cells) for adults with untreated non-small cell lung (NSCLC) without driver mutations (i.e. EGFR/ALK excluded from study) that was classified as locally advanced had spread other parts body (metastatic NSCLC). Researchers wanted see whether...
Objective To investigate the clinical efficacy of different treatment in 35 chronic lymphocytic leukemia (CLL) patients. Methods Patients were treated with regimen according to Binet stage. at stage A subcutaneously injected interferon (3-6) MU/day, consecutive for 5 days every week. The dosage could be reduced 2-3 times a week long term maintenance phase after 6 months loading if there was no disease progression. Those B or C initially chemotherapy FC/FC -R CHOP/COP, and administered during...